Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic mediators of acquired resistance to immunotherapy in metastatic melanoma.

Cancer cell - 10 Feb 2025

Schiantarelli Julia, Benamar Mouadh, Park Jihye, Sax Haley E, Oliveira Giacomo, Bosma-Moody Alice, Campbell Katie M, Liu David, Johnson Douglas B, Rodig Scott, Wu Catherine J, Hodi F Stephen, Ribas Antoni, Van Allen Eliezer, Haq Rizwan

Abstract excerpt

Although some patients with metastatic melanoma experience durable responses to immune checkpoint inhibitors (ICIs), most exhibit intrinsic or acquired resistance to these therapies. Here, we compare somatic genomic profiles from matched pre-treatment and post-resistance tumor biopsies in patients (n = 25) with metastatic melanoma who exhibited heterogeneous ICI responses to nominate additional mediators of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to JAK1 gene

Share to Immune Checkpoint Inhibitors

Share to Immunotherapy

Share to Melanoma

Share to Membrane Proteins

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 39933900
DOI: 10.1016/j.ccell.2025.01.009
PMCID: PMC12232206

Genes

SEC24C
B2M
JAK1
SEC24D

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic mediators of acquired resistance to immunotherapy in metastatic melanoma.PMID 39933900Read ↗

Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response RatesSemantic proximity Read ↗

The molecular and functional landscape of resistance to immune checkpoint blockade in melanomaSemantic proximity Read ↗

Molecular patterns of resistance to immune checkpoint blockade in melanomaSemantic proximity Read ↗

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.Semantic proximity Read ↗

Molecular patterns of resistance to immune checkpoint blockade in melanomaSemantic proximity Read ↗

Molecular Mechanisms of Resistance to Immune Checkpoint Inhibitors in Melanoma Treatment: An UpdateSemantic proximity Read ↗

Specific Aneuploidies Predict Immune Evasion and Poor Immunotherapy Response in MelanomaSemantic proximity Read ↗

Multi-organ landscape of therapy-resistant melanomaSemantic proximity Read ↗

HSPG2 Mutation Association with Immune Checkpoint Inhibitor Outcome in Melanoma and Non-Small Cell Lung CancerSemantic proximity Read ↗

Somatic mutations in tumor-infiltrating lymphocytes impact on antitumor immunity.Semantic proximity Read ↗

Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockadeSemantic proximity Read ↗

Unmasking PD-1 Resistance by Next-Generation SequencingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.